Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
Cancer Cell|December 9, 2008
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosisNeil P Shah, Corynn Kasap, Christopher Weier, et al.
Cancer Cell|September 3, 2002
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P Shah, John M Nicoll, Bhushan Nagar, et al.
Cureus|July 3, 2023
Elbow Evaluation Via Telephone and Video VisitRock P Vomer, David Carfagno, Adam Lewno, et al.
Leukemia Research|October 7, 2009
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinibRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
Cancer Research|March 12, 2009
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformationsMarkus A Seeliger, Pratistha Ranjitkar, Corynn Kasap, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2002
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopSergei Roumiantsev, Neil P Shah, Mercedes E Gorre, et al.
European Journal of Medicinal Chemistry|December 6, 2023
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691LXiuqi Wang, Rosa Anna DeFilippis, Tsigereda Weldemichael, et al.
The Journal of Clinical Investigation|August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah, Brian J Skaggs, Susan Branford, et al.
Cancer Genetics|August 30, 2011
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitorsRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Cancer Cell|December 9, 2008
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosisNeil P Shah, Corynn Kasap, Christopher Weier, et al.
Cancer Cell|September 3, 2002
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P Shah, John M Nicoll, Bhushan Nagar, et al.
Cureus|July 3, 2023
Elbow Evaluation Via Telephone and Video VisitRock P Vomer, David Carfagno, Adam Lewno, et al.
Leukemia Research|October 7, 2009
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinibRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
Cancer Research|March 12, 2009
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformationsMarkus A Seeliger, Pratistha Ranjitkar, Corynn Kasap, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2002
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopSergei Roumiantsev, Neil P Shah, Mercedes E Gorre, et al.
European Journal of Medicinal Chemistry|December 6, 2023
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691LXiuqi Wang, Rosa Anna DeFilippis, Tsigereda Weldemichael, et al.
The Journal of Clinical Investigation|August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyNeil P Shah, Brian J Skaggs, Susan Branford, et al.
Cancer Genetics|August 30, 2011
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitorsRonald L Paquette, John Nicoll, Meenal Chalukya, et al.
American Journal of Hematology|August 19, 2015
Clinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P Shah, Nicola Wallis, Harrison W Farber, et al.
Pageof 12